SERPINA1 reduces the risk of cardiac amyloidosis by inhibiting plasmin-mediated transthyretin hydrolysis and aggregation [47]; it modulates the Eph receptor B2 signaling pathway to improve energy metabolism and glucose homeostasis, thereby influencing cardiometabolic diseases [48]. Here, PLG is linked to cardiac amyloidosis.